Finding. Mitochondrial transplantation is the idea that you can add organelles the way you add a drug. Kontos, Roberts and colleagues take mitochondria from L6 skeletal-muscle myotubes and put them on H9C2 cardiomyocytes, with or without phenylephrine to drive hypertrophy. Fluorescent guest mitochondria show up inside the heart cells. Within 24 hours, Complex I-linked oxidative phosphorylation (OXPHOS) capacity rises (p=0.005) and maximal respiration rises (p=0.022). Phenylephrine enlarges the cells. Transplantation blunts that area increase. A 4,806-protein proteome says the mitochondrial set is enriched (OXPHOS, respiration, fatty-acid and amino-acid metabolism) while extracellular-matrix remodeling and de-differentiation signatures fall, in both healthy and stressed cells. The authors stop there: in vitro only, in-vivo work still required.
Why this paper matters
Right-ventricular hypertrophy is a mitochondrial disease as much as a wall-stress disease, and transplant papers often skip the middle: did the organelles arrive, did respiration move, did the proteome look like more mitochondria and less scar talk? This one answers those three in a line. It does not answer a patient.
The donor choice is the other sentence. Skeletal-muscle mitochondria into a cardiac line is a logistics decision (you can grow L6) and a biology risk (wrong proteome, wrong antigens). The unique signature they claim is how you will tell those apart later.
How to read the score
Mid-eighties. Direct mitochondrial therapy, quantitative respiration, a hypertrophy rescue, and a large proteome. Medium confidence because the system is a cell line plus a catecholamine, and the authors correctly refuse the disease claim.
Caveats
H9C2 is not a human ventricle. Phenylephrine is not pulmonary hypertension. Acute 24-hour OXPHOS is not engraftment. Allogeneic muscle mitochondria in a heart will have an immune story this brief cannot see. Do not write "mitochondrial transplant treats hypertrophy" from the abstract.
What to do with it
If you run transplant protocols, steal the QC stack: fluorescence, Complex I-linked and maximal respiration at 24 hours, cell area, then a mitochondrial-versus-ECM proteome. If you review the field, file this under mechanism, not under right-ventricular failure. Pull the in-vivo follow-up before you raise the score.